NCCN Tumor Boards: Optimizing Clinical Decision-Making for Resectable Non-Small Cell Lung Cancer

May 7, 2026

Due to recent FDA approvals, several types of perioperative systemic therapies are now available for the treatment of resectable non-metastatic non-small cell lung cancer. To ensure that these patients are receiving the most appropriate therapies, clinicians need to understand how to identify candidates for the various types of neoadjuvant and/or adjuvant therapy options. Clinicians should also recognize how molecular testing should be used to inform clinical decision-making when treating patients with resectable non-small cell lung cancer.  

Target Audience

This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Recognize the importance of using a multidisciplinary team approach when evaluating treatment options for patients with resectable non-small cell lung cancer.
  • Identify neoadjuvant and adjuvant therapy options available for the treatment of resectable non-small cell lung cancer.
  • Describe the role of molecular testing in identifying appropriate systemic therapy options for patients with resectable non-small cell lung cancer.

You may also be interested in

Recorded Presentations from the NCCN 2025 Lung Cancer Congress

This congress focuses on providing education for the interprofessional oncology care team with practical guidance on the latest updates to the NCCN Guidelines, novel and emerging therapies, recent clinical research, and strategies to align new developments with current standards of care. 
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Azurity Pharmaceuticals
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Novartis

This activity is supported by an independent medical education grant from AbbVie.

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
02/13/2026
Course expires: 
07/26/2026
Event starts: 
05/07/2026 - 2:00pm EDT
Event ends: 
05/07/2026 - 3:00pm EDT
Part of: 
NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
Add to calendar: 
Jessica R. Bauman, MD
Fox Chase Cancer Center

Stacey Su, MD
Fox Chase Cancer Center
 
NCCN Continuing Education Disclosure Policy
 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
 
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions  
 
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
 
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
 
The faculty listed below have no financial relationship(s) with ineligible companies to disclose.
 
Stacey Su, MD
 
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
 
Jessica R. Bauman, MD
AVEO Pharmaceuticals, Inc.: Consulting Fee
Johnson & Johnson: Scientific Advisor
Delcath Systems: Scientific Advisor
Fortvita: Scientific Advisor
Merus: Scientific Advisor
Pfizer Inc.: Scientific Advisor
 
NCCN Staff Disclosures
 
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-037-L01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission to provide continuing education credit to CCM® Board-Certified Case Managers. The course is approved for 1.0 CE contact hour.  Activity Code: S00067038; Approval Number: 260001117.
To claim these CEs, log into your dashboard at www.yourcommission.org.  

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Please login or register to take this course.

Click the Take Course button to claim credit for the live webinar.

This webinar was presented live one time only on Thursday, May 7, 2026. The recorded activity will be available in approximately one week.

 

NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing